

# Oklahoma Health Care Authority

## Drug Utilization Review Board

### (DUR Board)

Meeting – April 14, 2021 @ 4:00pm

## Oklahoma Health Care Authority (OHCA) Webinar

Please register for the meeting at:

[https://zoom.us/webinar/register/WN\\_p6\\_EPdLkQ8aw\\_rG7VewQXQ](https://zoom.us/webinar/register/WN_p6_EPdLkQ8aw_rG7VewQXQ)

After registering, you will receive a confirmation email containing information about joining the webinar.

## **AGENDA**

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

### **1. Call to Order**

A. Roll Call – Dr. Wilcox

#### **DUR Board Members:**

Dr. Stephen Anderson –  
Dr. Jennifer de los Angeles –  
Ms. Jennifer Boyett –  
Dr. Markita Broyles –  
Dr. Theresa Garton –  
Dr. Megan Hanner –  
Dr. Lynn Mitchell –  
Dr. John Muchmore –  
Dr. Lee Muñoz –  
Dr. James Osborne –

#### **Telephone Conference Participants**

participating via Zoom teleconference  
participating via Zoom teleconference  
participating via Zoom teleconference  
participating via Zoom teleconference  
participating via Zoom teleconference  
participating via Zoom teleconference  
participating via Zoom teleconference  
participating via Zoom teleconference  
participating via Zoom teleconference  
participating via Zoom teleconference

### **Public Access to Meeting via Zoom:**

Please register for the meeting at:

[https://zoom.us/webinar/register/WN\\_p6\\_EPdLkQ8aw\\_rG7VewQXQ](https://zoom.us/webinar/register/WN_p6_EPdLkQ8aw_rG7VewQXQ)

Or join by phone:

Dial: +1-253-215-8782 or +1-346-248-7799

Webinar ID: 934 3290 1479

Passcode: 72711553

### **Public Comment for Meeting:**

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting [www.okhca.org/DUR](http://www.okhca.org/DUR) and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to [DURPublicComment@okhca.org](mailto:DURPublicComment@okhca.org). Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.

Items to be presented by Dr. Muchmore, Chairman:

### **2. Public Comment Forum**

A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

**3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**

- A. March 10, 2021 DUR Minutes – Vote
- B. March 10, 2021 DUR Recommendation Memorandum

Items to be presented by Dr. Ha, Dr. Nawaz, Dr. Muchmore, Chairman:

**4. Update on Medication Coverage Authorization Unit/SoonerPsych Program Update – See Appendix B**

- A. Pharmacy Helpdesk Activity for March 2021
- B. Medication Coverage Activity for March 2021
- C. SoonerPsych Program Update

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

**5. Action Item – Vote to Prior Authorize Bafiertam™ (Monomethyl Fumarate), Kesimpta® (Ofatumumab), and Zeposia® (Ozanimod) – See Appendix C**

- A. New U.S. Food and Drug Administration (FDA) Approval(s)
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Ratterman, Dr. Muchmore, Chairman:

**6. Action Item – Vote to Prior Authorize Sevenfact® [Coagulation Factor VIIa (Recombinant)-jncw] – See Appendix D**

- A. Introduction
- B. Oklahoma Health Care Authority Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

**7. Action Item – Vote to Prior Authorize Sogroya® (Somapacitan-beco) – See Appendix E**

- A. New U.S. Food and Drug Administration (FDA) Approval(s)
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

**8. Action Item – Vote to Prior Authorize Nyvepria™ (Pegfilgrastim-apgf) – See Appendix F**

- A. New U.S. Food and Drug Administration (FDA) Approval(s)
- B. Nyvepria™ (Pegfilgrastim-apgf) Product Summary
- C. Cost Comparison: Pegfilgrastim Products
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

**9. Action Item – Vote to Prior Authorize Barhemsys® (Amisulpride) – See Appendix G**

- A. New U.S. Food and Drug Administration (FDA) Approval(s)
- B. Barhemsys® (Amisulpride) Product Summary
- C. Cost Comparison: Anti-Emetics for Postoperative Nausea and Vomiting (PONV)
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

**10. Vote to Prior Authorize Orladeyo™ (Berotralstat) – See Appendix H**

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

**11. Vote to Prior Authorize Breyanzi® (Lisocabtagene Maraleucel), Monjuvi® (Tafasitamab-cxix), Romidepsin 27.5mg/5.5mL Vial, Tecartus™ (Brexucabtagene Autoleucel), and Ukoniq™ (Umbralisib) – See Appendix I**

- A. New U.S. Food and Drug Administration (FDA) Approval(s) and Indication(s)

B. College of Pharmacy Recommendations

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

**12. Action Item – Annual Review of Antihypertensive Medications – See Appendix J**

- A. Current Prior Authorization Criteria
- B. Utilization of Antihypertensive Medications
- C. Prior Authorization of Antihypertensive Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Antihypertensive Medications

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

**13. Annual Review of Lung Cancer Medications and 30-Day Notice to Prior Authorize Cosela™ (Trilaciclib), Gavreto™ (Pralsetinib), Retevmo™ (Selpercatinib), Tabrecta™ (Capmatinib), and Zepzelca™ (Lurbinectedin) – See Appendix K**

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Lung Cancer Medications
- D. Market News and Updates
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Lung Cancer Medications

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

**14. Annual Review of Ayvakit™ (Avapritinib), Bynfezia Pen™ (Octreotide), and Tazverik® (Tazemetostat) – See Appendix L**

- A. Current Prior Authorization Criteria
- B. Utilization of Ayvakit™ (Avapritinib), Bynfezia Pen™ (Octreotide), and Tazverik® (Tazemetostat)
- C. Prior Authorization of Ayvakit™ (Avapritinib), Bynfezia Pen™ (Octreotide), and Tazverik® (Tazemetostat)
- D. Market News and Updates
- E. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

**15. Annual Review of Anti-Diabetic Medications and 30-Day Notice to Prior Authorize Lyumjev™ (Insulin Lispro-aabc) – See Appendix M**

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Diabetic Medications
- C. Prior Authorization of Anti-Diabetic Medications
- D. Market News and Updates
- E. Lyumjev™ (Insulin Lispro-aabc) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Non-Insulin Anti-Diabetic Medications
- H. Utilization Details of Insulin Medications

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

**16. Annual Review of Muscular Dystrophy Medications and 30-Day Notice to Prior Authorize Amondys 45™ (Casimersen), Viltepso® (Viltolarsen), and Vyondys 53™ (Golodirsen) – See Appendix N**

- A. Current Prior Authorization Criteria
- B. Utilization of Muscular Dystrophy Medications
- C. Prior Authorization of Muscular Dystrophy Medications
- D. Market News and Updates
- E. Product Summaries

- F. Cost Comparison: Duchenne Muscular Dystrophy (DMD) Exon-Skipping Therapies
- G. College of Pharmacy Recommendations
- H. Utilization Details of Muscular Dystrophy Medications

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

**17. Annual Review of Heart Failure Medications and 30-Day Notice to Prior Authorize Verquvo® (Vericiguat) – See Appendix O**

- A. Current Prior Authorization Criteria
- B. Utilization of Heart Failure Medications
- C. Prior Authorization of Heart Failure Medications
- D. Market News and Updates
- E. Verquvo® (Vericiguat) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Heart Failure Medications

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

**18. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix P**

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

**19. Future Business\* (Upcoming Product and Class Reviews)**

- A. Annual Review of the Pharmacy Benefit
- B. Alzheimer's Disease Medications
- C. Bladder Control Medications
- D. Various Systemic Antibiotics

*\*Future product and class reviews subject to change.*

**20. Adjournment**

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.